Journal
SCIENCE
Volume 321, Issue 5895, Pages 1493-1495Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1158554
Keywords
-
Categories
Funding
- NIH [AA11147]
- Stanford's SPARK Program
Ask authors/readers for more resources
There is substantial interest in the development of drugs that limit the extent of ischemia- induced cardiac damage caused by myocardial infarction or by certain surgical procedures. Here, using an unbiased proteomic search, we identified mitochondrial aldehyde dehydrogenase 2 ( ALDH2) as an enzyme whose activation correlates with reduced ischemic heart damage in rodent models. A high- throughput screen yielded a small- molecule activator of ALDH2 ( Alda- 1) that, when administered to rats before an ischemic event, reduced infarct size by 60%, most likely through its inhibitory effect on the formation of cytotoxic aldehydes. In vitro, Alda- 1 was a particularly effective activator of ALDH2*2, an inactive mutant form of the enzyme that is found in 40% of East Asian populations. Thus, pharmacologic enhancement of ALDH2 activity may be useful for patients with wild- type or mutant ALDH2 who are subjected to cardiac ischemia, such as during coronary bypass surgery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available